Members of the U.S. Senate and Congress are no strangers to making highly lucrative and frequently unorthodox stock picks, with their timing and success rates being such that many firmly believe they are acting on insider information.While Nancy Pelosi is the most recognizable among the politician-traders – thanks to both her impressive investing skill and her tenure as the Speaker of the House – Senator Tommy Tuberville is no laggard when it comes to stock market returns.Late in March, in fact, Tuberville ...

U.S. Senator Tommy Tuberville disclosed the purchase of Humacyte Inc. (NASDAQ: HUMA) stocks on April 15. Four days later, HUMA’s stock saw a 43% price surge, raising alerts of suspicious trading activity.Finbold retrieved trading data from Quiver Quantitative on Friday, April 19, with details on Tuberville’s disclosure. In particular, the U.S. Senator bought between $ 1,001 and $15,000 in Humancyte’s shares on March 21.HUMA was priced at $3.6 per share then, rendering around 11.67% gains for Tommy Tubervill ...

A U.S. Senator Just Bought this Tiny Stock - It's Up 15% Today Shuttesrtock / Gdisalvo Tommy Tuberville, a Republican Senator from the state of Alabama, disclosed 19 new stock trades on April 15th, and one trade in particular is causing big movements in the underlying stock. Tuberville reported 3 trades in Humacyte (Nasdaq: HUMA). The stock is now up 18.5% the past five days, including a 15% gain today. Let’s dive into the details of why this Congressional trade is turning heads. Humacyte is a Biotechnolo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ___________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39532 Humacyte, Inc. (Exact name of registrant as specified in its charter) ___ ...

Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Conference Call March 22, 2024 8:00 AM ET Company Participants Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Conference Call Participants Ryan Zimmerman - BTIG Kristen Kluska - Cantor Fitzgerald & Co. Joshua Jennings - TD Cowen Allison Bratzel - Piper Sandler Vernon Bernardino - H.C. Wainwright Operator Good morning, ladies a ...

Exhibit 99.1 -Raised approximately $43.1 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- DURHAM, N.C., March 22, 2024 – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the in ...

Humacyte, Inc. (NASDAQ:HUMA) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Suraj Kalia - Oppenheimer Bruce Jackson - The Benchmark Company Good afternoon, ladies and gentlemen, and welcome to the Humacyte Third Quarter Results Conference Call. Currently, all participants are in a listen-only mode. Later, we wil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to __ ...

Humacyte Inc. (NASDAQ:HUMA) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Dr. Laura Niklason - President & CEO Dale Sander - CFO & Chief Corporate Development Officer Dr. Heather Prichard - COO Laura Marek - LifeSci Advisors, IR Ryan Zimmerman - BTIG Josh Jennings - TD Cowen Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer & Company Bruce Jackson - The Benchmark Company. Good morning, ladies and gentlemen, and welcome to the Humacyte Second Quarter Results Conference Call. Currently, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or ...